Science and Products
Research and development equipment
Yongtai Biological has established a production quality management system that meets GMP standards, equipped with automated antibody coating isolators, incubators, centrifuges, flow cytometers, microbial identification instruments, and other production and quality inspection equipment. The independently developed intelligent devices and closed culture system components enable sterile operations under Class C conditions, effectively preventing product contamination. At the same time, the company employs NAT rapid mycoplasma testing methods and rapid sterility testing methods for quality control of cell products, addressing key technical challenges in the large-scale production and quality inspection of immune cell drugs, achieving standardized and industrialized production of immune cell drugs.
The company has nearly 80 core technology patents in key steps such as cell preparation. Now it has established a pipeline of 10 + genes and cell products for different cancer species, covering gene modification/non-gene modification, multi-target/single target, with target indications covering solid tumors, blood tumors, virus infection and other related diseases. Research and development progress is at the international advanced level. The company has undertaken a number of scientific research projects, such as the National 863 Project, the National Nature Fund, the Ministry of Industry and Information Technology High-quality Development Project, the Beijing Science and Technology Innovation Fund, and the National Ministry of Science and Technology Major New Drug Creation.
As of June 2024, a total of five immune cell therapy products have entered clinical trials. Core Product EAL®It is an immune cell therapy product approved to enter the Phase II clinical trial of solid tumor treatment in China, and will be included in the list of CDE breakthrough treatment varieties in September 2023, which is expected to fill the gap of immune cell therapy in the field of solid tumors in China. At the same time, with aT19, RC19D2, CAR-T-19 injection and other three approved gene-modified cell drugs into clinical trials, and the perfect combination of two gene-modified product TCR-T-CMV and TCR-T-EBV for infection after hematopoietic stem cell transplantation, a rich research and development layout of immune cell therapy product pipelines in the field of hematological tumors has been formed.
Next Page